Beyond chemotherapy: new agents for targeted treatment of lymphoma. Friedberg, J. New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Cancer Res. Hagberg, H.
Article Google Scholar. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am. Program , — Chen, W. The clinicopathological analysis of cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. PubMed Article Google Scholar. Good, D. Classification of non-Hodgkin's lymphoma.
North Am. Tan, L. A practical approach to the understanding and diagnosis of lymphoma: an assessment of the WHO classification based on immunoarchitecture and immuno-ontogenic principles. Pathology 41 , — LoRusso, P. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Ledford, H. Translational research: 4 ways to fix the clinical trial. Nature , — Robertson, M. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Advani, R. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
Lancet Oncol. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood , — Arrowsmith, J. Trial watch: phase III and submission failures: — Drug Discov. Alizadeh, A. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Hess, G. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. Hanahan, D. Hallmarks of cancer: the next generation.
Cell , — Chin, L. Cancer genomics: from discovery science to personalized medicine. Chapman, P. Kwak, E. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. Pasqualucci, L. Analysis of the coding genome of diffuse large B-cell lymphoma. Morin, R. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Cairns, R. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Kridel, R. Lohr, J. Natl Acad. USA , — Yao, J. Everolimus for advanced pancreatic neuroendocrine tumors. Motzer, R. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet , — Johnston, P.
Witzig, T. Leukemia 25 , — Smith, S. Activity of single agent temsirolimus CCI in non-mantle cell non-Hodgkin lymphoma subtypes [abstract]. Kahl, B. Significant clinical activity of cal, an isoform-selective inhibitor of phosphatidylinositol 3 kinase pd, in patients with relapsed or refractory indolent and mantle cell lymphoma [abstract].
Google Scholar. Fowler, N. A phase I trial of Btk inhibitor PCI in patients with relapsed non-Hodgkin's lymphoma: evidence of antitumor activity [abstract]. Haematologica 95 , Utility of mTOR inhibition in hematologic malignancies. Oncologist 16 , — Wang, L. The Bruton's tyrosine kinase inhibitor PCI is highly active as single-agent therapy in previously-treated mantle cell lymphoma MCL : preliminary results of a phase II trial [abstract].
Iqbal, J. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. Casasnovas, R. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.
Article PubMed Google Scholar. Korenberg, M. Predicting survival in follicular lymphoma using tissue microarrays. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Biomarker detection and tumor sample collection meet the following standards:. Try the modernized ClinicalTrials. Learn more about the modernization effort.
Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details. Last Update Posted : October 14, See Contacts and Locations. Study Description. This study is an open-label, multicenter, umbrella study aimed to evaluate the combined, biomarker-driven, targeted treatment efficiency of Pamiparib, Bevacizumab, Tislelizumab, and Nab-paclitaxel in patients with platinum-resistant recurrent ovarian cancer PROC.
Detailed Description:. MedlinePlus related topics: Ovarian Cancer. FDA Resources. Drug: Docetaxel Injectable Solution Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Drug: Radium Chloride Ra Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC. Experimental: Treatment 1: Enzalutamide Assignments to therapy in the biomarker driven arms will be done on the basis of the biomarker signature using the current information about the efficacy of the various regimens for that signature.
Information from previous studies may be incorporated in the randomization at study onset if such reliable data exists. Specifically, patients with an intact androgen receptor AR and without TP53 mutations will have increased chance of being randomized to treatment of Abiraterone or Enzalutamide. Experimental: Treatment 2: Abiraterone Patients with an intact androgen receptor AR and without TP53 mutations will have an increased chance of being randomised to treatment of Abiraterone or Enzalutamide.
Experimental: Treatment 3: Carboplatin DNA-repair deficient patients will have an increased chance of receiving Carboplatin. Experimental: Treatment 6: Niraparib plus Abiraterone acetate plus Prednisone DNA-repair deficient patients will have an increased chance of receiving the combination treatment with Niraparib plus Abiraterone acetate plus Prednisone. Drug: Niraparib plus Abiraterone acetate plus Prednisone Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents.
Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC. Treatment costs will be based on drug costs and reimbursement data. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Try the modernized ClinicalTrials. Learn more about the modernization effort. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U.
Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Last Update Posted : October 6, See Contacts and Locations. Study Description. Show detailed description.
Hide detailed description. Detailed Description:. MedlinePlus related topics: Prostate Cancer. FDA Resources. Arms and Interventions. Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC Summary of Product Characteristics. Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Assignments to therapy in the biomarker driven arms will be done on the basis of the biomarker signature using the current information about the efficacy of the various regimens for that signature.
0コメント